Malignant Lymphoma

Modern Study Review (AI-Generated)

High-Yield Summary

Primary malignant lymphoma of bone (PLB) is a rare extranodal non-Hodgkin lymphoma originating within the bone, typically presenting in young adults. It most commonly affects the distal femur or proximal tibia and is characterized by localized bone pain and swelling without systemic symptoms. Early diagnosis and combined modality treatment with chemotherapy and radiotherapy have significantly improved survival outcomes. Understanding its distinct radiographic and histopathologic features is critical for differentiation from other primary bone tumors.

Key Diagnostic Findings

Anatomy

• Typical Sites: Distal femur, proximal tibia, and other long bones, often involving the diaphysis or metaphysis.
• Pathophysiology: Tumor arises within the medullary cavity and remains localized for at least 6 months before systemic spread.

Clinical Presentation

• Symptoms: Localized bone pain and swelling, sometimes with a palpable soft tissue mass.
• Systemic Signs: Usually absent constitutional symptoms (e.g., fever, weight loss) at presentation.

Imaging

• X-rays:
• Poorly defined, permeative or moth-eaten lytic lesions in the diaphysis or metaphysis.
• Mixed lytic and sclerotic patterns possible.
• Periosteal reaction and cortical thickening may be present but are nonspecific.
• Advanced Imaging: MRI and PET/CT are used for staging and assessing soft tissue involvement.

Classification Systems

• No specific bone lymphoma classification system; diagnosis relies on histopathology and lymphoma subtype classification (e.g., WHO classification of lymphoid neoplasms).
• Most cases are Diffuse Large B-Cell Lymphoma (DLBCL) subtype.

Current Gold Standard Treatment

Non-operative

• Chemotherapy: Multi-agent regimens (e.g., R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) are the cornerstone.
• Radiotherapy: Localized radiotherapy to involved bone improves local control and is often combined with chemotherapy.

Operative

• Surgery is generally limited to biopsy and stabilization of pathological fractures.
• Radical resection is not standard due to lymphoma’s high chemo- and radiosensitivity.

Modern Complications & Outcomes

Complications

• Pathological fractures due to bone destruction.
• Local recurrence or progression to systemic lymphoma if untreated.
• Treatment-related toxicities (e.g., chemotherapy-induced cytopenias, radiation-induced fibrosis).

Outcomes

• 5-year overall survival ranges from 60-80% with modern combined chemo-radiotherapy, significantly improved from historical 20-50%.
• Prognosis depends on stage, presence of extraosseous disease, and response to therapy.
• Early diagnosis and treatment are critical to preserving function and reducing morbidity.

Classic Clinical Notes

Malignant Lymphoma

• Definition: Primary malignant lymphoma of bone = tumor arising within bone & remaining localized at the original site without extraosseous involvement for at least 6 months.
• Epidemiology: Usually presents in the 3rd decade involving distal femur or proximal femur.

Signs & Symptoms

• Pain & swelling at tumor site +/- tender soft tissue mass.
• Usually no constitutional symptoms.

X-rays

• Poorly marginated, destructive permeative lesion in diaphysis of long bones.
• May be lytic, sclerotic, or a mixture of both.
• Periosteal reaction with cortical thickening.

Histology

• Diffuse infiltration of round lymphoid cells varying from small to large cells which have grooved nuclei & conspicuous nucleoli.
• Areas of spindle cell proliferation with fibrosis.
• Usually large B-cell type lymphocytes.

Treatment

• Radiation & chemotherapy.
• 5-year survival = 20-50% depending on presence of extraosseous lesions.

Last Updated on January 25, 2026 by orthonet